Evidence map›Paper›PMID 37678101›Full record

ArticleParkinsonism & related disorders2023

Utilizing speech analysis to differentiate progressive supranuclear palsy from Parkinson's disease.

Kyurim Kang, Adonay S Nunes, Mansi Sharma, A J Hall, Ram Kinker Mishra, Jose Casado, Rylee Cole, Marc Derhammer, Gregory Barchard, Bijan Najafi and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Parkinsonism & related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Voice and Speech in Atypical Parkinsonian Disorders.Movement disorders clinical practice · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kyurim KangJohns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, 21287, USA.
Adonay S NunesBioSensics LLC, Newton, MA, 02458, USA.
Mansi SharmaMassachusetts General Hospital, Harvard Medical School, Department of Neurology, Boston, MA, USA.
A J HallJohns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, 21287, USA.
Ram Kinker MishraBioSensics LLC, Newton, MA, 02458, USA.
Jose CasadoBioSensics LLC, Newton, MA, 02458, USA.
Rylee ColeBioSensics LLC, Newton, MA, 02458, USA.
Marc DerhammerBioSensics LLC, Newton, MA, 02458, USA.
Gregory BarchardBioSensics LLC, Newton, MA, 02458, USA.
Bijan NajafiInterdisciplinary Consortium for Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, 77030, USA.
Ashkan VaziriBioSensics LLC, Newton, MA, 02458, USA.
Anne-Marie WillsMassachusetts General Hospital, Harvard Medical School, Department of Neurology, Boston, MA, USA.
Alexander PantelyatJohns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, 21287, USA. Electronic address: apantel1@jhmi.edu.
BioSensics (United States) · USJohns Hopkins University · USHarvard University · USBaylor College of Medicine · US

Funding

BIOMARKER DISCOVERY AND VALIDATION IN PSPU01NS102035 · NINDS · JOHNS HOPKINS UNIVERSITY · PI PANTELYAT, ALEXANDER Y. · 2018 to 2022
$4.5M
Phase IIB: A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration SyndromesR44AG080861 · NIA · BIOSENSICS, LLC · PI ADAM L. BOXER, Irene Litvan · 2022 to 2026
$3.5M
Multi-modal magnetic resonance imaging in progressive supranuclear palsy (PSP)K23AG059891 · NIA · JOHNS HOPKINS UNIVERSITY · PI PANTELYAT, ALEXANDER Y. · 2018 to 2022
$968k
NIA NIH HHS K23 AG059891NIA NIH HHS R44 AG080861NINDS NIH HHS U01 NS102035
6 · The paper itself

Abstract

introductionDistinguishing Parkinson's disease (PD) from Progressive supranuclear palsy (PSP) at early disease stages is important for clinical trial enrollment and clinical care/prognostication.

methodsWe recruited 21 participants with PSP(n = 11) or PD(n = 10) with reliable caregivers. Standardized passage reading, counting, and sustained phonation were recorded on the BioDigit Home tablet (BioSensics LLC, Newton, MA USA), and speech features from the assessments were analyzed using the BioDigit Speech platform (BioSensics LLC, Newton, MA USA). An independent t-test was performed to compare each speech feature between PSP and PD participants. We also performed Spearman's correlations to evaluate associations between speech measures and clinical scores (e.g., PSP rating scales and MoCA). In addition, the model's performance in classifying PSP and PD was evaluated using Rainbow passage reading analysis.

resultsDuring Rainbow passage reading, PSP participants had a significantly slower articulation rate (2.45(0.49) vs 3.60(0.47) words/minute), lower speech-to-pause ratio (2.33(1.08) vs 3.67(1.18)), intelligibility dynamic time warping (DTW, 0.26(0.19) vs 0.53(0.26)), and similarity DTW (0.43(0.27) vs 0.67(0.13)) compared to PD participants. PSP participants also had longer pause times (17.24(5.47) vs 8.45(3.13) sec) and longer total signal times (52.44(6.67) vs (36.67(6.73) sec) when reading the passage. In terms of the phonation 'a', PSP participants showed a significant higher spectral entropy, spectral centroid, and spectral spread compared to PD participants and no differences were found for phonation 'e'. PD participants had more accurate reverse number counts than PSP participants (14.89(3.86) vs 7.36(4.67)). PSP Rating Scale (PSPRS) dysarthria (r = 0.79, p = 0.004) and bulbar item scores (r = 0.803, p = 0.005) were positively correlated with articulation rate in reverse number counts. Correct reverse number counts were positively correlated with total Montreal Cognitive Assessment scores (r = 0.703, p = 0.016). Machine learning models using passage reading-derived measures obtained an AUC of 0.93, and the sensitivity/specificity in correctly classifying PSP and PD participants were 0.95 and 0.90, respectively.

conclusionOur study demonstrates the feasibility of differentiating PSP from PD using a digital health technology platform. Further multi-center studies are needed to expand and validate our initial findings.

Indexed as

Parkinson DiseaseSupranuclear Palsy, ProgressiveDysarthriaHumansSensitivity and SpecificitySpeechDigital biomarkersMachine learningParkinsonismRemote patient monitoringSpeech assessments

Identifiers

PMID37678101
PMCPMC10591790
OpenAlexW4386319122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.